Plans for a new approach to EU health and pharmaceuticals policy

Following the recent announcements of a new EU4Health Programme, and publication of a Roadmap on timely patient access to affordable medicines, the EU Commission has now launched a far-reaching consultation on its plans for a Pharmaceutical Strategy for Europe. Some of the challenges brought into sharp focus by the COVID-19 crisis will be...

A prioritisation model for COVID 19

By L. Gordon Moore, MD, Senior Medical Director, Clinical Strategy and Value based Care for 3M Health Information Systems How might a health system use existing health information to inform a data-driven priority focussed model in response to COVID 19? Health authorities globally are faced with gaps between supplies and...

MHRA update on COVID-19 – 15 June 2020

The below is an update from the MHRA - 15/06/2020 - on the Coronavirus situation For more information on Coronavirus, click here This notice updates you on details of recently published guidance for industry on the coronavirus (COVID-19) pandemic and how we are working closely with our healthcare partners to...

Evolution in the law affecting cannabis-based products

We recently reviewed the law on cannabis-based medicines. It is clear that changes in scientific data and social attitudes mean that producers are faced with rapid evolution and differences in regulatory approach between countries, not only for medicines but for other products too. E-cigarettes containing CBD illegal in France A French case...

What is R&D for tax purposes?

A common question with a complex answer. When claiming R&D Tax Relief, your business must be performing eligible R&D activity – but what is R&D for tax purposes and what is eligible R&D activity? What is R&D? R&D stands for research and development. ‘Research and development’ are the activities a...

An update from the QbDVision team

The COVID-19 pandemic has put the pharma and biotech industries once again at the forefront of leading the world’s efforts to fight back against another insidious threat. Here at CherryCircle Software, it has ignited our team to fulfil our mission to help in this fight by bringing industry-leading software solutions...

Janet Worrell Joins Ranks of Regulatory Professionals

Medilink EM Patron Jenson R+ are extremely delighted to announce that Janet Worrell (Head of Regulatory)  has been made a fellow of TOPRA (The Organisation for Professionals in Regulatory Affairs). Janet has over 30 years of pharmaceutical industry experience, with 29 years gained continuously in the regulatory field. Prior to working...